AbCellera Biologics Inc. (ABCL)
| Market Cap | 1.18B |
| Revenue (ttm) | 38.03M |
| Net Income (ttm) | -146.40M |
| Shares Out | 292.78M |
| EPS (ttm) | -0.51 |
| PE Ratio | n/a |
| Forward PE | 27.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,012,806 |
| Open | 4.010 |
| Previous Close | 3.970 |
| Day's Range | 3.980 - 4.250 |
| 52-Week Range | 3.790 - 8.050 |
| Beta | 0.36 |
| Analysts | Strong Buy |
| Price Target | 19.00 (+373.82%) |
| Earnings Date | May 7, 2024 |
About ABCL
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for ABCL stock is "Strong Buy." The 12-month stock price forecast is $19.0, which is an increase of 373.82% from the latest price.
News
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024.
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) will announce its first quarter 2024 financial results on Tuesday, May 7, 2024, and hold an earnings conference call at...
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Bloom Burton Healthcare Conference on Tuesday, Apr...
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target th...
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that its scientists will present four posters with data from its T-cell engager programs and platform a...
AbCellera Announces Resignation of Board Member
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Direct...
AbCellera to Present at Upcoming Investor Conferences in March
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences: 44th Annual TD Cow...
AbCellera Reports Full Year 2023 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2023. All financial information in this press release is reported i...
AbCellera to Report Full Year 2023 Financial Results on February 20, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) will announce its full year 2023 financial results on Tuesday, February 20, 2024, and hold an earnings conference call ...
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on W...
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023.
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023.
AbCellera Reports Q3 2023 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2023 Business Results.
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
WILMINGTON, Del. & VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology...
AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023.
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023.
AbCellera Announces Two T-Cell Engager Presentations at SITC 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Two T-Cell Engager Presentations at SITC 2023.
AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron.
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology.
AbCellera Reports Q2 2023 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q2 2023 Business Results.
AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights' Request for Rehearing
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights' Request for Rehearing.
AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023.
Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera
GHENT, Belgium--(BUSINESS WIRE)--Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has entered into a research collabora...
AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023.
AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced a CA$701 million co-investment with the Governments of Canada and British Columbia to build new capabil...